PDCD1 and cancer: The researchers observed good therapeutic efficacy after administering AK104 (a PD-1/CTLA-4 BSAB) in combination with XELOX (capecitabine plus oxaliplatin) or modified XELOX in patients with unresectable advanced G/GEJ cancer.